On April 2, 2024 Invenra Inc., an innovative leader in bispecific antibody technology, reported a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions (Press release, Invenra, APR 2, 2024, View Source [SID1234641722]). The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-discover novel bispecific antibody-drug conjugates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Roland Green, CEO of Invenra, remarks, "We are excited to collaborate with the innovative team at Catalent’s Redwood Bioscience subsidiary. We believe that the combination of Invenra’s B-Body bispecific antibody platform with Catalent’s SMARTag ADC expertise has the potential to unlock synergies and accelerate the development of next-generation cancer therapeutics."

Both companies share a commitment to developing novel therapeutic solutions with the potential to make a meaningful impact in the lives of patients.